Search results for " Prospective"

showing 10 items of 244 documents

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.

2009

International audience; BACKGROUND: Reports of an increased risk of lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease are controversial. We assessed this risk in a prospective observational cohort study. METHODS: 19,486 patients with inflammatory bowel disease, of whom 11,759 (60.3%) had Crohn's disease and 7727 (39.7%) had ulcerative colitis or unclassified inflammatory bowel disease, were enrolled in a nationwide French cohort by 680 gastroenterologists, who reported details of immunosuppressive therapy during the observation period, cases of cancer, and deaths. The risk of lymphoproliferative disorder was assessed according to thiopurine expos…

MaleTime FactorsMESH : Age DistributionMESH : Prospective StudiesMESH : AgedInflammatory bowel diseaseMESH: Proportional Hazards Models0302 clinical medicineMESH: Lymphoproliferative DisordersCrohn DiseaseRisk FactorsMESH: Risk FactorsMESH : PurinesMESH : FemaleProspective StudiesMESH: IncidenceProspective cohort studyMESH : Immunosuppressive AgentsMESH : Sex DistributionMESH: AgedMESH : Tumor Necrosis Factor-alphaCrohn's diseaseMESH: Middle AgedThiopurine methyltransferasebiologyMESH : Lymphoproliferative DisordersIncidenceMESH: Sex DistributionGeneral MedicineMESH: PurinesMiddle AgedMESH : AdultMESH : Colitis UlcerativeUlcerative colitisMESH : Risk FactorsMESH : Incidence3. Good health030220 oncology & carcinogenesisCohortDrug Therapy CombinationFemale030211 gastroenterology & hepatology[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyFranceMESH: Immunosuppressive AgentsImmunosuppressive AgentsCohort studyMESH : Time FactorsAdultmedicine.medical_specialtyMESH : MaleMESH: Colitis UlcerativeLymphoproliferative disordersMESH : Crohn DiseaseMESH: Multivariate Analysis03 medical and health sciencesAge DistributionInternal medicinemedicineHumansMESH : Middle AgedSex DistributionMESH : FranceMESH: Age DistributionAgedProportional Hazards ModelsMESH: HumansMESH: Crohn DiseaseTumor Necrosis Factor-alphabusiness.industryMESH : Drug Therapy CombinationMESH: Time FactorsMESH : HumansMESH : Multivariate AnalysisMESH: Adult[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterologymedicine.diseaseMESH : Proportional Hazards ModelsLymphoproliferative DisordersMESH: MaleMESH: Prospective StudiesSurgeryMESH: FranceMESH: Drug Therapy CombinationPurinesMESH: Tumor Necrosis Factor-alphaMultivariate Analysisbiology.proteinColitis UlcerativebusinessMESH: Female
researchProduct

The impact of frailty on ICU and 30-day mortality and the level of care in very elderly patients (≥ 80 years)

2017

Purpose: Very old critical ill patients are a rapid expanding group in the ICU. Indications for admission, triage criteria and level of care are frequently discussed for such patients. However, most relevant outcome studies in this group frequently find an increased mortality and a reduced quality of life in survivors. The main objective was to study the impact of frailty compared with other variables with regards to short-term outcome in the very old ICU population. Methods: A transnational prospective cohort study from October 2016 to May 2017 with 30 days follow-up was set up by the European Society of Intensive Care Medicine. In total 311 ICUs from 21 European countries participated. Th…

MaleTime FactorsOutcome AssessmentFrail Elderly/statistics & numerical data[SDV]Life Sciences [q-bio]HSJ UCIPassiveCritical Care and Intensive Care MedicineFrailty/classification/diagnosis/mortality/therapySeverity of Illness IndexSeverity of illneElderly0302 clinical medicineQuality of lifeElderly; Frailty; ICU; Mortality; Octogenarians; Severity of illness; Aged 80 and over; Critical Illness; Europe; Euthanasia Passive; Female; Frail Elderly; Frailty; Geriatric Assessment; Humans; Intensive Care Units; Length of Stay; Male; Outcome Assessment Health Care; Proportional Hazards Models; Prospective Studies; Quality of Life; Severity of Illness Index; Time Factors; Hospital MortalityOutcome Assessment Health Care80 and overProspective StudiesHospital Mortality030212 general & internal medicineProspective cohort studyAged 80 and overeducation.field_of_studyddc:617FrailtyMortality rate[SDV] Life Sciences [q-bio]EuropeIntensive Care UnitsLength of Stay/statistics & numerical dataCohortIntensive Care Units/statistics & numerical dataCritical IllneFemaleSOFA scoreHumanmedicine.medical_specialtyOctogenariansTime FactorCritical IllnessFrail ElderlyIntensive Care UnitPopulationINTENSIVE-CARESeverity of illnessEurope/epidemiologyOutcome Assessment (Health Care)03 medical and health sciencesOctogenarianIntensive careSeverity of illnessJournal ArticlemedicineHumansCOHORTMortalityOctogenarinansIntensive care medicineeducationGeriatric AssessmentAgedProportional Hazards ModelsOLDEREuthanasiabusiness.industry030208 emergency & critical care medicineLength of StayEuthanasia PassiveHealth CareProspective StudieCritical Illness/mortalityUNITICUEmergency medicineProportional Hazards ModelQuality of LifebusinessIntensive Care Medicine
researchProduct

Augmentation of tibial plateau fractures with an injectable bone substitute: CERAMENT™. Three year follow-up from a prospective study

2015

Background: Reduction of tibial plateau fractures and maintain a level of well aligned congruent joint is key to a satisfactory clinical outcome and is important for the return to pre-trauma level of activity. Stable internal fixation support early mobility and weight bearing. The augmentation with bone graft substitute is often required to support the fixation to mantain reduction. For these reasons there has been development of novel bone graft substitutes for trauma applications and in particular synthetic materials based on calcium phosphates and/or apatite combined with calcium sulfates. Injectable bone substitutes can optimize the filling of irregular bone defects. The purpose of this…

MaleTime FactorsPercutaneousKnee Jointmedicine.medical_treatmentDentistryFracture Fixation InternalFracture FixationTibial plateau fracture Surgical treatment Bone graft Ceramic injectable biphasic bone substitute Clinical and radiographic outcomeFracture fixationTibial plateau fractureOrthopedics and Sports MedicineProspective StudiesTomographyFracture HealingSurgical treatmentBone TransplantationMiddle AgedCombined Modality TherapyBiomechanical PhenomenaX-Ray ComputedDrug CombinationsTreatment Outcomemedicine.anatomical_structureSettore MED/03FemaleResearch ArticleAdultmedicine.medical_specialtyBone healingCalcium SulfateInjectionsRheumatologyClinical and radiographic outcomeTibial plateau fracturemedicineBone graftHumansInternal fixationTibiaTibiabusiness.industryRecovery of Functionmedicine.diseaseInternalSurgeryTibial FracturesDurapatiteCeramic injectable biphasic bone substituteIrregular boneBone SubstitutesOrthopedic surgeryAdult; Biomechanical Phenomena; Bone Substitutes; Bone Transplantation; Calcium Sulfate; Combined Modality Therapy; Drug Combinations; Durapatite; Female; Follow-Up Studies; Fracture Fixation Internal; Fracture Healing; Humans; Injections; Knee Joint; Male; Middle Aged; Prospective Studies; Recovery of Function; Tibia; Tibial Fractures; Time Factors; Tomography X-Ray Computed; Treatment OutcomeTomography X-Ray ComputedbusinessFollow-Up StudiesBMC Musculoskeletal Disorders
researchProduct

Elective segmental ureterectomy for transitional cell carcinoma of the ureter: Long-term follow-up in a series of 73 patients

2012

What's known on the subject? and What does the study add? Upper Urinary Tract (UUT) Transitional Cell Carcinoma (TCC) is an uncommon disease and represents approximately 5% of all urothelial carcinomas. We report our series on 73 patients treated with Kidney Sparing Surgery for UUT TCC. Good results have been achieved in terms of oncological outcome comparing this conservative approach to the radical nephrourectomy. OBJECTIVES: • To report the long-term oncological outcome in patients with transitional cell carcinoma of the ureter electively treated with kidney-sparing surgery. • To compare our data with the few series reported in the literature. PATIENTS AND METHODS: • We considered 73 pat…

MaleTime FactorsTime FactorBiopsyUrologyConservative treatment; Segmental ureterectomy; Transitional cell carcinoma; Upper urinary tract; Ureter; Aged; Aged 80 and over; Biopsy; Carcinoma Transitional Cell; Elective Surgical Procedures; Female; Follow-Up Studies; Humans; Italy; Male; Middle Aged; Prospective Studies; Survival Rate; Time Factors; Treatment Outcome; Ureter; Ureteral Neoplasms; Ureteroscopy; Urologic Surgical Procedures; UrologyFollow-Up StudieTransitional cell carcinoma80 and overUreteroscopyHumansProspective StudiesAgedAged 80 and overCarcinoma Transitional CellElective Surgical ProcedureUreteral NeoplasmsCarcinomaMiddle AgedUreteral NeoplasmSurvival RateConservative treatment; Segmental ureterectomy; Transitional cell carcinoma; Upper urinary tract; UreterProspective StudieTreatment OutcomeItalyElective Surgical ProceduresUrologic Surgical ProcedureUpper urinary tractUrologic Surgical ProceduresSegmental ureterectomyFemaleTransitional CellUreterConservative treatmentFollow-Up StudiesHuman
researchProduct

Cerebral haemodynamic changes during propofol-remifentanil or sevoflurane anaesthesia: transcranial Doppler study under bispectral index monitoring

2006

Background. Sevoflurane or propofol–remifentanil-based anaesthetic regimens represent modern techniques for neurosurgical anaesthesia. Nevertheless, there are potential differences related to their activity on the cerebrovascular system. The magnitude of such difference is not completely known. Methods. In total 40 patients, treated for spinal or maxillo-facial disorders, were randomly allocated to either i.v. propofol–remifentanil or inhalational sevoflurane anaesthesia. Transcranial Doppler was used to assess changes in cerebral blood flow velocity, carbon dioxide reactivity, cerebral autoregulation and the bispectral index to assess the depth of anaesthesia. Results. Time-averaged mean f…

MaleUltrasonography Doppler TranscranialHemodynamicsBlood PressurePiperidinesHeart RateMedicineHomeostasisProspective StudiesPropofolUltrasonographyIntraoperativeAdult Anesthetics; Combined; pharmacology Anesthetics; Inhalation; Intravenous; pharmacology Blood Flow Velocity; drug effects Blood Pressure; drug effects Carbon Dioxide; physiology Cerebrovascular Circulation; drug effects Electroencephalography Female Heart Rate; drug effects Homeostasis; drug effects Humans Male Methyl Ethers; pharmacology Middle Aged Monitoring; Intraoperative; methods Piperidines; pharmacology Propofol; pharmacology Prospective Studies Ultrasonography; Doppler; TranscranialCombineddrug effectDopplerElectroencephalographyMiddle AgedAnesthetics CombinedCerebral blood flowInhalationBispectral indexAnesthesiaCerebrovascular CirculationAnesthetics InhalationmethodFemaleIntravenousPropofolAnesthetics IntravenousBlood Flow Velocitymedicine.drugHumanMethyl EthersAdultMonitoringRemifentanilIntravenouTranscranialCerebral autoregulationtranscranial DopplerSevofluranemethodsRemifentanilSevofluranePiperidineMonitoring IntraoperativeHomeostasiHumansAnestheticsbusiness.industryAnestheticCarbon DioxideTranscranial DopplerProspective StudieAnesthesiology and Pain MedicineMethyl Etherdrug effectsphysiologypharmacologybusiness
researchProduct

Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study

2021

Peri-operative SARS-CoV-2 infection increases postoperative mortality. The aim of this study was to determine the optimal duration of planned delay before surgery in patients who have had SARS-CoV-2 infection. This international, multicentre, prospective cohort study included patients undergoing elective or emergency surgery during October 2020. Surgical patients with pre-operative SARS-CoV-2 infection were compared with those without previous SARS-CoV-2 infection. The primary outcome measure was 30-day postoperative mortality. Logistic regression models were used to calculate adjusted 30-day mortality rates stratified by time from diagnosis of SARS-CoV-2 infection to surgery. Among 140,231…

MaleVascular damage Radboud Institute for Health Sciences [Radboudumc 16]MULTICENTERinfectious diseases0302 clinical medicine030202 anesthesiologyAnesthesiologyCirugía80 and overProspective StudiesYoung adultChildLungAged 80 and overCOVID-19 ; delay ; SARS-CoV-2 ; surgery ; timingSARS‐CoV‐2 infectionOperativeChild PreschoolPneumonia & InfluenzaInfectionCohort studyHumanmedicine.medical_specialtydelayClinical SciencesSars-cov-2GlobalSurg CollaborativeSettore MED/28 - MALATTIE ODONTOSTOMATOLOGICHE03 medical and health sciencesClinical ResearchAnesthesiologyBiodefenseCorrespondence617HumansPULMONARY COMPLICATIONSCRIANÇAS EM IDADE PRÉ-ESCOLARAgedScience & TechnologyCirurgiaPreventionCOVID-19; SARS-CoV-2; delay; surgery; timingInfantOdds ratioPneumoniaProspective StudieClinical research/dk/atira/pure/core/keywords/uob_covid19SurgeryHuman medicine610 Medizin und Gesundheit1109 NeurosciencesInternationalitySettore MED/29 - CHIRURGIA MAXILLOFACCIALESettore MED/18 - CHIRURGIA GENERALECOVID-19; delay; SARS-CoV-2; surgery; timing; Adolescent; Adult; Aged; Aged 80 and over; Child; Child Preschool; Cohort Studies; Female; Humans; Infant; Male; Middle Aged; Prospective Studies; SARS-CoV-2; Surgical Procedures Operative; Time; Young Adult; COVID-19; Internationality; Practice Guidelines as TopicgastroenterologyCohort StudiessurgeryMedicine and Health Sciencestiming030212 general & internal medicineProspective cohort studyMortality rateCOVID-19; delay; SARS-CoV-2; surgery; timingCovid19Middle AgedInfectious DiseasesSurgical Procedures OperativePractice Guidelines as TopicFemalePatient Safetymedicine.symptom6.4 SurgeryLife Sciences & BiomedicineAdult61Adolescent610 Medicine & healthCOVID-19 SARS-CoV-2 delay surgery timingAsymptomaticNOCOVIDSurg CollaborativeTimeVaccine RelatedYoung AdultAll institutes and research themes of the Radboud University Medical CentermedicineMortalitatddc:610MortalityPreschoolLS7_4Surgical Proceduresbusiness.industrySARS-CoV-2NeurosciencesEvaluation of treatments and therapeutic interventionsCOVID-191103 Clinical Sciences3126 Surgery anesthesiology intensive care radiologySurgeryReconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10]Anesthesiology and Pain MedicineEmerging Infectious DiseasesGood Health and Well BeingMortalidadCohort Studiebusiness
researchProduct

Dexamethasone for unresponsive diabetic macular oedema: optical coherence tomography biomarkers

2019

Purpose: To analyse the effects of intravitreal dexamethasone implant (DEX) in patients with diabetic macular oedema (DME) unresponsive to ranibizumab treatment, in relation to the inflammatory optical coherence tomography (OCT) retinal features, subfoveal neuroretinal detachment (SND) and hyperreflective retinal spots (HRS). Methods: Patients with DME poorly responsive to three injections of ranibizumab were treated with DEX. Best-corrected visual acuity (BCVA) and central macula thickness (CMT, measured by Spectralis SD-OCT) were assessed at baseline and at 1, 3, and 6 months. Results: Overall, 44 eyes were included in the study. In the whole group, mean BCVA (baseline 51.5 ± 8.3 letters)…

MaleVisual acuitygenetic structuresVisual AcuityAngiogenesis InhibitorsDrug Implantchemistry.chemical_compound0302 clinical medicineGlucocorticoidMacula LuteaProspective StudiesFluorescein AngiographyProspective cohort studyTomographyDrug Implantsmedicine.diagnostic_testGeneral MedicineDiabetic retinopathyDrug ToleranceFluorescein angiographyTreatment Outcomediabetic macular oedemaIntravitreal InjectionsFemalemedicine.symptomDrugTomography Optical Coherencemedicine.drugAngiogenesis InhibitorHumanmedicine.medical_specialtyFundus Oculibest-corrected visual acuity; dexamethasone; diabetes retinopathy; diabetic macular oedema; optical coherence tomography; ranibizumab; Aged; Angiogenesis Inhibitors; Dexamethasone; Diabetic Retinopathy; Dose-Response Relationship Drug; Drug Implants; Drug Tolerance; Female; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Glucocorticoids; Humans; Intravitreal Injections; Macula Lutea; Macular Edema; Male; Prospective Studies; Ranibizumab; Tomography Optical Coherence; Treatment Outcome; Visual AcuitydexamethasoneMacular EdemaFollow-Up StudieDose-Response Relationship03 medical and health sciencesOphthalmologyRanibizumabmedicineHumansMacular edemaGlucocorticoidsDexamethasoneAgedbest-corrected visual acuity; dexamethasone; diabetes retinopathy; diabetic macular oedema; optical coherence tomography; ranibizumab; Aged; Angiogenesis Inhibitors; Dexamethasone; Diabetic Retinopathy; Dose-Response Relationship; Drug; Drug Implants; Drug Tolerance; Female; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Glucocorticoids; Humans; Intravitreal Injections; Macula Lutea; Macular Edema; Male; Prospective Studies; Ranibizumab; Tomography; Optical Coherence; Treatment Outcome; Visual Acuityoptical coherence tomographyDiabetic RetinopathyDose-Response Relationship Drugbusiness.industryIntravitreal InjectionRetinalmedicine.diseaseeye diseasesOphthalmologyProspective StudiechemistryOptical Coherence030221 ophthalmology & optometrysense organsRanibizumabbusinessdiabetes retinopathy030217 neurology & neurosurgerybest-corrected visual acuityFollow-Up Studies
researchProduct

Opioid-induced or pain relief-reduced symptoms in advanced cancer patients?

2006

Abstract Background While opioids in increasing doses may produce adverse effects, the same adverse effects may be associated with poor pain control. Moreover, in the clinical setting symptomatic treatment and illness may balance the outcome of opioid titration. Some adverse effects may tend to disappear continuing the treatment in a long-term period. Aims The aim of this study was to monitor the effects of a rapid opioid titration combined with symptomatic treatment in patients with poor relief and to monitor these changes in the following period of 20 days. Methods A consecutive sample of 35 patients admitted to an acute Pain Relief and Palliative Care Unit were titrated with opioids, acc…

MaleWeaknessPalliative careConstipationNauseaOpioid-induced symptoms; pain relief; advanced cancer patients; longitudinal prospective studymedia_common.quotation_subjectPainpain reliefadvanced cancer patientlongitudinal prospective studyNeoplasmsmedicineHumansLongitudinal StudiesProspective StudiesAdverse effectmedia_commonbusiness.industryPalliative CareAppetiteMiddle AgedAnalgesics OpioidAnesthesiology and Pain MedicineOpioidPatient SatisfactionAnesthesiaEmergency MedicineVomitingFemalemedicine.symptomCancer painbusinessOpioid-induced symptommedicine.drug
researchProduct

Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxe…

2010

There is currently no standard of treatment for patients with hormone refractory prostate cancer (HRPC) after failure of docetaxel-based chemotherapy. The purpose of this study was to assess the anticancer activity and tolerance of metronomic cyclophosphamide prednisolone combination in this setting.From 2005 to 2010, patients with HRPC who failed at least docetaxel-based chemotherapy were proposed metronomic cyclophosphamide-prednisolone regimen, and were prospectively registered. Twenty-three patients received 50 mg cyclophosphamide and 10 mg prednisolone per os daily until disease progression. Treatment tolerance and efficacy on PSA decrease and pain were studied.Metronomic cyclophospham…

Male[SDV.IMM] Life Sciences [q-bio]/ImmunologyMESH : Antineoplastic Combined Chemotherapy ProtocolsMESH: Treatment FailurePrednisoloneMESH : MaleMESH : PrednisoloneMESH: TaxoidsMESH : AgedMESH : Prospective StudiesDocetaxelMESH : Treatment OutcomeMESH : Treatment FailureMESH: Aged 80 and overAntineoplastic Combined Chemotherapy ProtocolsHumans[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyMESH : Middle AgedProspective StudiesTreatment FailureMESH : Prostate-Specific AntigenMESH : Aged 80 and overMESH : TaxoidsCyclophosphamideMESH : Cyclophosphamidehealth care economics and organizationsAgedMESH: Treatment OutcomeAged 80 and overMESH: AgedMESH: HumansMESH: Middle AgedMESH : HumansProstatic NeoplasmsMESH: CyclophosphamideMiddle AgedProstate-Specific AntigenMESH: MaleMESH: Prospective StudiesMESH: Prostate-Specific AntigenMESH: Antineoplastic Combined Chemotherapy ProtocolsTreatment OutcomeMESH: Prostatic Neoplasms[SDV.IMM]Life Sciences [q-bio]/ImmunologyTaxoidsMESH: PrednisoloneMESH : Prostatic Neoplasms
researchProduct

Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort

2019

Introduction: Concerns about dolutegravir (DTG) tolerability in the real-life setting have recently arisen. We aimed to estimate the risk of treatment discontinuation and virological failure of DTG-based regimens from a large cohort of HIV-infected individuals. Methods: We performed a multicentre, observational study including all antiretroviral therapy (ART)-naïve and virologically suppressed treatment-experienced (TE) patients from the Icona (Italian Cohort Naïve Antiretrovirals) cohort who started, for the first time, a DTG-based regimen from January 2015 to December 2017. We estimated the cumulative risk of DTG discontinuation regardless of the reason and for toxicity, and of virologica…

Maleadverse eventadverse events; antiretroviral therapy; cohort study; discontinuation; dolutegravir; toxicity; Adult; Anti-HIV Agents; Cohort Studies; Dideoxynucleosides; Female; HIV Infections; Heterocyclic Compounds 3-Ring; Humans; Italy; Male; Middle Aged; Prospective Studies; Retrospective Studies; Tenofovir; Treatment Outcomeadverse events; antiretroviral therapy; cohort study; discontinuation; dolutegravir; toxicity;HIV InfectionsPiperazinesCohort Studies0302 clinical medicineHeterocyclic CompoundsAbacavirRetrospective StudieMedicineHIV InfectionProspective Studies030212 general & internal medicineProspective cohort studyResearch Articlesadverse events; antiretroviral therapy; cohort study; discontinuation; dolutegravir; toxicityHazard ratioMiddle AgedDideoxynucleosidedolutegravirTreatment OutcomeInfectious DiseasesTolerabilityItalyCohortFemalePublic Health0305 other medical scienceHeterocyclic Compounds 3-RingResearch Articlemedicine.drugHumanAdultmedicine.medical_specialtyAnti-HIV AgentsPyridonesantiretroviral therapySettore MED/17 - MALATTIE INFETTIVE3-RingLower riskNO03 medical and health sciencesInternal medicineOxazinescohort studyHumansTenofovirRetrospective Studies030505 public healthbusiness.industryEnvironmental and Occupational HealthPublic Health Environmental and Occupational HealthAnti-HIV AgenttoxicityRetrospective cohort studyantiretroviral therapy; dolutegravir; cohort study; discontinuation; toxicity; adverse eventsDideoxynucleosidesadverse eventsDiscontinuationProspective Studieadverse events; antiretroviral therapy; cohort study; discontinuation; dolutegravir; toxicity; Public Health Environmental and Occupational Health; Infectious DiseasesCohort Studiebusinessdiscontinuation
researchProduct